Brokerages Set Elevance Health, Inc. (NYSE:ELV) PT at $399.63

Elevance Health, Inc. (NYSE:ELV) has received an average recommendation of “Moderate Buy” from the twenty-two analysts that are currently covering the firm, Marketbeat.com reports. Nine research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $396.90.

Several brokerages have recently commented on ELV. Barclays decreased their price objective on Elevance Health from $404.00 to $393.00 and set an “overweight” rating for the company in a report on Friday. Zacks Research raised Elevance Health from a “strong sell” rating to a “hold” rating in a research report on Thursday, November 6th. Jefferies Financial Group decreased their price target on Elevance Health from $401.00 to $395.00 and set a “buy” rating for the company in a research note on Friday. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $332.00 price target on shares of Elevance Health in a report on Thursday. Finally, Wolfe Research set a $425.00 price objective on shares of Elevance Health and gave the company an “outperform” rating in a report on Thursday, January 8th.

Elevance Health Price Performance

ELV opened at $345.62 on Thursday. The business’s 50-day moving average is $351.69 and its two-hundred day moving average is $328.98. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.56. Elevance Health has a 1 year low of $273.71 and a 1 year high of $458.75. The firm has a market capitalization of $76.81 billion, a PE ratio of 13.76, a price-to-earnings-growth ratio of 1.88 and a beta of 0.51.

Elevance Health (NYSE:ELV) last posted its earnings results on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, beating analysts’ consensus estimates of $3.10 by $0.23. The company had revenue of $49.31 billion during the quarter, compared to analysts’ expectations of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. Elevance Health’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Research analysts anticipate that Elevance Health will post 33.96 earnings per share for the current fiscal year.

Elevance Health Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be issued a $1.72 dividend. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date of this dividend is Tuesday, March 10th. Elevance Health’s dividend payout ratio is 27.23%.

Institutional Trading of Elevance Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Physician Wealth Advisors Inc. raised its stake in shares of Elevance Health by 331.6% in the third quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock worth $26,000 after purchasing an additional 63 shares during the last quarter. Activest Wealth Management increased its holdings in Elevance Health by 66.7% in the 3rd quarter. Activest Wealth Management now owns 85 shares of the company’s stock worth $27,000 after buying an additional 34 shares during the period. Rossby Financial LCC increased its holdings in Elevance Health by 110.0% in the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after buying an additional 44 shares during the period. Vermillion & White Wealth Management Group LLC raised its position in Elevance Health by 94.9% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock worth $30,000 after buying an additional 37 shares during the last quarter. Finally, BOK Financial Private Wealth Inc. acquired a new stake in Elevance Health during the 2nd quarter valued at approximately $32,000. Institutional investors and hedge funds own 89.24% of the company’s stock.

Trending Headlines about Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q4 earnings beat consensus (EPS beat and strong profit print), which sparked an earlier rally and helped lift investor sentiment. Elevance Health (NYSE:ELV) Stock Price Up 6.3% on Strong Earnings
• Positive Sentiment: Leerink Partners nudged its price target up to $357 and maintained a “market perform” rating, a modest vote of confidence that signals upside potential from current levels. Leerink Partners adjusts price target on Elevance Health to $357
• Positive Sentiment: Consensus broker sentiment remains constructive (average “Moderate Buy”), which provides some support for the shares as analysts digest results and guidance. Elevance Health, Inc. Given Average Recommendation of “Moderate Buy”
• Neutral Sentiment: Company Q4 call and published highlights provide detail on membership shifts, margin dynamics and the drivers behind the quarter — useful for longer-term modeling but not a clear immediate catalyst. ELV Q4 2025 Earnings Call Highlights
• Negative Sentiment: Management forecast for 2026 profit came in below some Street estimates and flagged an anticipated revenue decline, which is the principal near-term headwind pressuring the stock. Elevance forecasts 2026 profit below estimates
• Negative Sentiment: Analysts and commentary highlighted margin pressures and membership shifts shaping a weaker 2026 outlook — narratives that have driven selloffs despite the quarterly beat. ELV Q4 Deep Dive: Margin Pressures and Membership Shifts
• Negative Sentiment: Regulatory context: a CMS proposal for only a modest Medicare Advantage rate increase added to near-term investor concern, contributing to a large negative move earlier in the week. Health Insurance Stock Could Rebound Off Historically Bullish Signal
• Negative Sentiment: Coverage pieces framed the results as “in line” but stressed the deteriorating outlook and ongoing industry headwinds, which has kept selling pressure on the shares after the initial post-earnings bounce. Elevance reports Q4 in line with expectations but stock drops

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.